Search Result
Results for "
restoring
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
3
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P1930A
-
|
Integrin
|
Inflammation/Immunology
|
Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .
|
-
-
- HY-103708
-
C2-deoxyhinokitiol; 4-Isopropyltropone
|
Drug Derivative
|
Others
|
Nezukone is a derivative of hinokitiol. Hinokitiol can restore iron transports, however, Nezukone cannot bind or transport iron.
|
-
-
- HY-101459
-
-
-
- HY-139142B
-
PTI-125 hydrochloride
|
mTOR
iGluR
Amyloid-β
Tau Protein
|
Neurological Disease
|
Simufilam hydrochloride (PTI-125 hydrochloride) is an orally active FLNA modulator. Simufilam hydrochloride restores NMDAR signaling and Arc expression. Simufilam hydrochloride inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam hydrochloride can be used for research of Alzheimer's disease .
|
-
-
- HY-136564A
-
|
Potassium Channel
|
Neurological Disease
|
DAD is a type of ion channel blocker that blocks voltage-gated potassium channels. DAD is a third-generation photoswitch that responds to visible light. DAD has the potential for restoring visual function .
|
-
-
- HY-136564
-
|
Potassium Channel
|
Neurological Disease
|
DAD dichloride is a type of ion channel blocker that blocks voltage-gated potassium channels. DAD dichloride is a third-generation photoswitch that responds to visible light. DAD dichloride has the potential for restoring visual function .
|
-
-
- HY-122057
-
|
Others
|
Others
|
Bisdionin F is a compound with the ability to restore the antibacterial function of macrophages, which can block the arginase activity induced by Candida albicans and restore the nitric oxide production and antibacterial function of macrophages.
|
-
-
- HY-161118
-
|
Others
|
Neurological Disease
|
MB327 is a bipyridine nonoxime compound that restores neuromuscular function. MB327 restores the activity of nicotinamide acetylcholine receptors (nAChRs) for carbachol desensitization in a typical type II PAM manner. MB327 can neutralize nerve agent poisoning .
|
-
-
- HY-P1930
-
|
Integrin
|
Inflammation/Immunology
|
Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .
|
-
-
- HY-N11872
-
|
Others
|
Neurological Disease
|
Suffruticosol A is a neuroprotective agent that restores scopolamine-induced cellular neurodegenerative damage. Suffruticosol A ameliorates hippocampal cholinergic deficits and partially enhances BDNF signaling. Suffruticosol A has neuromodulatory effects in a Scopolamine (HY-N0296)-induced model, restoring memory and cognitive performance in mice. Suffruticosol A can be isolated from seeds of P. lactiflora .
|
-
-
- HY-139142
-
PTI-125
|
mTOR
iGluR
Amyloid-β
Tau Protein
|
Neurological Disease
|
Simufilam (PTI-125) is an orally active FLNA modulator. Simufilam restores NMDAR signaling and Arc expression. Simufilam inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ42-induced neuroinflammation and tau protein hyperphosphorylation.
Simufilam can be used for research of Alzheimer's disease .
|
-
-
- HY-139142A
-
PTI-125 dihydrochloride
|
Tau Protein
Amyloid-β
mTOR
iGluR
|
Neurological Disease
|
Simufilam dihydrochloride (PTI-125 dihydrochloride) is an orally active FLNA modulator. Simufilam dihydrochloride restores NMDAR signaling and Arc expression. Simufilam dihydrochloride inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam dihydrochloride can be used for research of Alzheimer's disease .
|
-
-
- HY-121520
-
-
-
- HY-N7981
-
|
NF-κB
|
Neurological Disease
|
Pratensein, a flavonoid, ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels .
|
-
-
- HY-N0435
-
|
Others
|
Neurological Disease
|
Isorhamnetin 3-gentiobioside protects the morphological structures and restores acetylcholine level in rat hippocampus, and improves brain functions via normalizing brain EEG .
|
-
-
- HY-117951
-
|
Beta-lactamase
|
Infection
|
ANT431 is a metallo-β-lactamase inhibitor that also restores the effectiveness of Meropenem (HY-13678) in a mouse thigh Escherichia coli infection model .
|
-
-
- HY-158977
-
|
Beta-lactamase
Bacterial
|
Infection
|
β-Lactamase-IN-9 (compound 2) is a β-lactamase inhibitor that can restore the sensitivity of pathogens to β-lactam antibiotics .
|
-
-
- HY-158002
-
-
-
- HY-145126
-
|
CFTR
|
Others
|
CP-628006, a small molecule CFTR potentiator, restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
|
-
-
- HY-W048303
-
|
Antibiotic
|
Infection
Cancer
|
L-Azatyrosine is an antitumor antibiotic isolated from Streptomyces chibaensis. L-Azatyrosine can restore normal phenotypic behavior to transformed cells bearing oncogenic Ras genes .
|
-
-
- HY-159649
-
|
DGK
|
Cancer
|
BMS-986408 is an orally active dual DGK α/ζ inhibitor that restores T cell-mediated anti-tumor immunity by enhancing T cell signaling .
|
-
-
- HY-18936
-
-
-
- HY-P5183
-
|
Sodium Channel
|
Neurological Disease
|
Hm1a is a disulfide-rich spider-venom peptide, and a NaV1.1 activator. Hm1a restores the function of inhibitory interneurons in Dravet syndrome (DS) mouse model .
|
-
-
- HY-168508
-
|
HDAC
|
Neurological Disease
|
PB200 is an HDAC6 inhibitor with an IC50 value of 1.97 nM. PB200 demonstrates significant antidepressant effects by restoring abnormal HDAC6 expression levels and alleviating neuroinflammation .
|
-
-
- HY-172904
-
-
-
- HY-114848
-
SM1213 hydrochloride; Therafectin hydrochloride
|
Others
|
Others
|
Amiprilose (SM1213) hydrochloride is a novel synthetic carbohydrate with anti-inflammatory and immunomodulatory properties, which can restore the number of painful and swollen joints, joint pain and swelling index, and grip strength to baseline levels.
|
-
-
- HY-169675
-
-
-
- HY-111348
-
Ro 44-9883
|
Integrin
|
Cardiovascular Disease
|
Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes .
|
-
-
- HY-19980A
-
PRIMA-1
2 Publications Verification
NSC-281668
|
Autophagy
MDM-2/p53
Ferroptosis
Apoptosis
|
Cancer
|
PRIMA-1 (NSC-281668) is a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
|
-
-
- HY-P9940
-
|
Factor VIII
|
Cardiovascular Disease
|
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .
|
-
-
- HY-B2195
-
|
Adrenergic Receptor
|
Metabolic Disease
|
Aidioxa has the ability to improve delayed gastric emptying in rats. It can partially improve delayed gastric emptying caused by clonidine or restraint stress. The allyltoin part of Aidioxa restores gastric emptying activity by antagonizing α-2 adrenergic receptors. Its aluminum hydroxide part is involved in restoring gastric compliance. Aidioxa can improve both delayed gastric emptying and impaired gastric compliance, both of which play an important role in functional dyspepsia (FD). Aidioxa is a candidate agent for inhibiting FD.
|
-
-
- HY-149762
-
|
Bacterial
|
Infection
|
IMBI (compound 32) is an antibacterial agent that inhibits quorum sensing (QS) against drug-resistant pathogens. IMBI inhibits biofilm formation of Salmonella marcescens and restores or increases its susceptibility to antimicrobial drugs .
|
-
-
- HY-108739
-
BI 655075
|
Thrombin
|
Cardiovascular Disease
|
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
|
-
-
- HY-159650
-
|
Adenosine Receptor
|
Cancer
|
EOS-984 is a highly potent and selective ENT1 (equilibrative nucleoside transporter 1) inhibitor. EOS-984 is designed to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation .
|
-
-
- HY-N3315
-
|
Others
|
Inflammation/Immunology
|
Massonianoside B is an antioxidant, which can be isolated from Cedrus deodara pine needle. Massonianoside B exhibits radicals scavenging capacities, and restores CCL4-impaired activity of antioxidant enzymes .
|
-
-
- HY-158151
-
|
MDM-2/p53
|
Cancer
|
p53 Activator 12 (compound 510B) is a potent p53 activator. p53 Activator 12 binds to mutant p53 and restores the ability of the p53 mutant to bind DNA .
|
-
-
- HY-P3333
-
|
MHC
|
Inflammation/Immunology
Cancer
|
KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .
|
-
-
- HY-119248
-
MK-0767
|
PPAR
|
Metabolic Disease
|
KRP-297 is a PPARα and PPARγ agonist potentially for the research of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.
|
-
-
- HY-170835
-
|
Beta-lactamase
Bacterial
|
Infection
Inflammation/Immunology
|
NDM-1 inhibitor-7 (Compound A8) is a NDM-1 inhibitor, with IC50 of 10.284 μM. NDM-1 inhibitor-7 restores the ability of MEM to penetrate the cell wall of gram-negative bacteria. NDM-1 inhibitor-7 effectively restores the antibacterial activity of MEM against NDM-1-positive Escherichia coli. NDM-1 inhibitor-7 demonstrates strong efficacy in both the Galleria mellonella infection model and murine peritonitis infection model .
|
-
-
- HY-147368
-
|
Pyruvate Kinase
|
Cancer
|
PKM2 activator 2 (compound 28) is a pyruvate kinase M2 (PKM2) activitor with an AC50 value of 66 nM. PKM2 activator 2 can restore normal glycolytic metabolism in cells .
|
-
-
- HY-105321A
-
PBT 2 hydrochloride
|
Bacterial
|
Neurological Disease
|
PBT 1033 hydrochloride is an orally active copper/zinc ionophore. PBT 1033 hydrochloride restores cognition in mouse models of Alzheimer's disease (AD). PB 1033 also has antibacterial activity against Gram-positive bacteria .
|
-
-
- HY-111348A
-
|
Integrin
|
Cardiovascular Disease
|
Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes .
|
-
-
- HY-170393
-
|
JAK
STAT
|
Cancer
|
iBFAR2, a BFAR inhibitor, restores the CD8+ TRM cell subset against solid tumors. iBFAR2 promotes JAK2-STAT1 association and STAT1 phosphorylation .
|
-
-
- HY-161460
-
-
-
- HY-W042156
-
|
Fungal
|
Neurological Disease
|
Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity .
|
-
-
- HY-P3333A
-
|
MHC
|
Inflammation/Immunology
Cancer
|
KSPWFTTL TFA is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL TFA can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .
|
-
-
- HY-118275
-
|
Cholinesterase (ChE)
|
Neurological Disease
|
FK960 is a potential anti-dementia agent that reverses the reduction in cerebral blood flow (rCBF) caused by sensory stimulation by enhancing cholinergic neurotransmission. In macaque experiments, physostigmine (AChE inhibitor; HY-N6608) was able to completely eliminate the rCBF in the sensory cortex increased by vibrotactile stimulation. FK960 (1-1000 μg/kg) can restore the eliminated rCBF response, and the action time can last for 1 hour. However, FK960 cannot restore the rCBF response eliminated by HA-966 (NMDA modulator; HY-100822), indicating that its function is not dependent on non-glutamatergic neurotransmission.
|
-
-
- HY-P9993
-
LY-3462817
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. Peresolimab can be used in research of rheumatoid arthritis .
|
-
-
- HY-144767
-
|
Bacterial
|
Infection
|
PA3552-IN-1 (compound 15) is an antibiotic adjuvant that restores sensitivity of MDR P. aeruginosa DK2 strain to Polymyxin B. PA3552-IN-1 can reduce PA3552 expression .
|
-
-
- HY-105321
-
PBT 2
|
Bacterial
|
Neurological Disease
|
PBT 1033 (PBT 2) is an orally active copper/zinc ionophore. PBT 1033 restores cognition in mouse models of Alzheimer's disease (AD). PB 1033 also has antibacterial activity against Gram-positive bacteria .
|
-
- HY-145721A
-
GED-0301 sodium
|
TGF-beta/Smad
|
Inflammation/Immunology
|
Mongersen sodium is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen sodium restores TGF-β1 activity leading to inhibition of inflammatory signals. Mongersen sodium can attenuate Crohn's disease-like experimental colitis in mice .
|
-
- HY-19726
-
|
MDM-2/p53
|
Cancer
|
NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway . NSC59984 acts by targeting GOF-mutant p53 and stimulates p73 to restore the p53 pathway signaling .
|
-
- HY-121431
-
|
Fungal
|
Inflammation/Immunology
|
FR-901235 is a new type of immunoactive substance produced by an imperfect fungus, Paecilomyces carneus F-4882. FR-901235 partially restored the impaired delayed-type hypersensitivity to sheep red blood cells in tumor-bearing mice .
|
-
- HY-N5190
-
|
Antibiotic
Bacterial
|
Infection
|
Enamidonin is a lipopeptide antibiotic. Enamidonin inhibits EGF-dependent [ 3H] thymidine involvement in Balb/MK cells (IC50 is 10 μg/mL), and it can restore the deformed SRCTS-NRK form to the normal flat form (ED50 is 10 μg/mL). No antimicrobial activity .
|
-
- HY-153092
-
BI-685509
|
Guanylate Cyclase
|
Cardiovascular Disease
Metabolic Disease
|
Avenciguat (BI-685509) is a potent and orally active sGC activator. Avenciguat restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. Avenciguat can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD) .
|
-
- HY-160696
-
|
CD73
|
Cancer
|
ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment .
|
-
- HY-145721
-
GED-0301
|
TGF-beta/Smad
|
Inflammation/Immunology
|
Mongersen (GED-0301) is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen restores TGF-β1 activity leading to inhibition of inflammatory signals. Mongersen can attenuate Crohn's disease-like experimental colitis in mice .
|
-
- HY-B1074
-
Etamsylate
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
|
Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis. .
|
-
- HY-120744
-
|
Tau Protein
|
Others
|
LDN-193665 is a Tau kinase inhibitor with tauopathy-modifying activity. LDN-193665 inhibits Tau phosphorylation, improves tauopathy in animal models, reduces Sarkosyl-insoluble Tau, and restores memory. It may be necessary to simultaneously target multiple kinases to effectively inhibit tauopathies.
|
-
- HY-126394B
-
VX-659 potassium
|
CFTR
|
Endocrinology
|
Bamocaftor potassium is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore F508del-CFTR protein function. Bamocaftor potassium can be used combine with Tezacaftor (HY-15448) and Ivacaftor (HY-13017) in cystic fibrosis research .
|
-
- HY-W016704
-
Gentisic acid sodium
|
Drug Derivative
|
Cardiovascular Disease
|
2,5-Dihydroxybenzoic acid (sodium) (Gentisic acid (sodium)) is a phenolic compound. 2,5-Dihydroxybenzoic acid (sodium) restores mean arterial pressure and reduces blood lactate concentration in animal models of sepsis and septic shock. 2,5-Dihydroxybenzoic acid (sodium) can be used in the study of septic shock related diseases .
|
-
- HY-111338
-
Tacrine
5 Publications Verification
|
Cholinesterase (ChE)
|
Neurological Disease
|
Tacrine is an effective oral acetylcholine (AChE) inhibitor (IC50 = 109 nM) and also acts as an active substrate for CYP1A2. Tacrine can restore cognitive dysfunction in elderly rats. Tacrine can cause liver toxicity and is used in research related to Alzheimer's disease .
|
-
- HY-P2624
-
|
PAK
|
Metabolic Disease
|
st-Ht31 is a membrane-permeable peptide inhibitor of protein kinase A (PKA) anchoring. st-Ht31 induces robust cholesterol/phospholipid efflux. st-Ht31 completely reverses foam cell formation and restores the metabolic health of macrophage .
|
-
- HY-155011
-
|
Bacterial
Antibiotic
|
Others
|
MB076 is a novel heterocyclic triazole with improved plasma stability. MB076 inhibits seven different Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with Ki values < 1 μM. MB076 acts synergistically in combination with multiple cephalosporins to restore pBCSK(−) susceptibility .
|
-
- HY-126394
-
VX-659
|
CFTR
|
Endocrinology
|
Bamocaftor (VX-659) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore F508del-CFTR protein function. Bamocaftor can be used combine with Tezacaftor (HY-15448) and Ivacaftor (HY-13017) in cystic fibrosis research .
|
-
- HY-156567
-
|
DGK
|
Metabolic Disease
|
AMB639752 is a potent DGKα inhibitor. AMB639752 restores restimulation induced cell death (RICD) in SAP deficient lymphocytes by inhibiting DGKα in intact cells. AMB639752 can be used for X-linked lymphoproliferative disease 1(XLP-1) research .
|
-
- HY-132584A
-
SRP-4045 sodium
|
Others
Dystrophin
|
Others
|
Casimersen sodium is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass. Casimersen sodium binds to exon 45 of dystrophin pre-mRNA, restores the open-reading frame (by skipping exon 45) resulting in the production of an internally truncated but functional dystrophin protein. Casimersen sodium can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
- HY-101282
-
|
Amyloid-β
|
Neurological Disease
|
Glutaminyl Cyclase Inhibitor 3 (compound 212 ), a designed anti-Alzheimer’s compound, is a potent human Glutaminyl Cyclase (GC) inhibitor, with an IC50 of 4.5 nM. Glutaminyl Cyclase-IN-1 (compound 212) significantly reduced the brain concentrations of pyroform Aβ and total Aβ and restored cognitive functions .
|
-
- HY-N14114
-
|
Fungal
|
Infection
|
Curvularol has weak anti-fungal activity and no anti-bacterial effect. Curvularol of 150 ng/mL inhibits the cell cycle progression of NRK in normal rats at G1 stage. Curvularol of 100 ng/mL can restore the morphology of SRC TS-deformed NRK cells. Curvularol inhibits protein synthesis .
|
-
- HY-N10429
-
(+)-Geissoschizoline
|
Cholinesterase (ChE)
|
Neurological Disease
Inflammation/Immunology
|
Geissoschizoline ((+)-Geissoschizoline) is a potent inhibitor of human AChE/BChE, with IC50s of 20.40 µM and 10.21 µM, respectively. Geissoschizoline emerges as a possible multi-target prototype that can be very useful in studies of preventing neurodegeneration and restoring neurotransmission. Geissoschizoline aiso is a potent anti-inflammatory agent .
|
-
- HY-119505
-
|
HDAC
|
Others
|
Curcuphenol is a compound with histone deacetylase enhancing activity and has the activity of reversing immune escape. Curcuphenol can reverse the immune escape of tumors by restoring the expression of antigen presentation machinery. Its two synthetic analogs have histone deacetylase enhancing activity and play an important role in the immune recognition of metastatic tumors.
|
-
- HY-124771
-
|
Apoptosis
|
Metabolic Disease
|
RH01386 is a small molecule that can prevent endoplasmic reticulum stress (ERS)-induced β cell dysfunction and death, and inhibits proapoptotic gene expression. RH01386 restores ERS-impaired glucose-stimulated insulin secretion responses. RH01386 has the potential for type 2 diabetes treatment .
|
-
- HY-162318
-
|
Molecular Glues
c-Myc
|
Cancer
|
MYC degrader 1 (compound A80.2HCl) is an orally available MYC molecular glues degrader with anti-tumor activity. MYC degrader 1 restores pRB1 protein activity and re-establishes sensitivity of MYC overexpressing cancer cells to CDK4/6 inhibitors .
|
-
- HY-W042156R
-
|
Fungal
|
Neurological Disease
|
Aegeline (Standard) is the analytical standard of Aegeline. This product is intended for research and analytical applications. Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity .
|
-
- HY-18935
-
Curaxin 137; CBL-C137
|
Histone Acetyltransferase
MDM-2/p53
NF-κB
|
Cancer
|
CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates NF-?B and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis .
|
-
- HY-168031
-
-
- HY-173128
-
|
Apoptosis
|
Infection
|
TZOA is an antiviral agent that inhibits the replication of infectious hematopoietic necrosis virus (IHNV) in a dose-dependent manner and significantly reduces viral titers. TZOA can effectively counteract IHNV-induced apoptosis, maintain mitochondrial membrane potential and homeostasis, and restore MAVS-mediated interferon expression. TZOA has antiviral activity .
|
-
- HY-138054
-
|
MDM-2/p53
|
Cancer
|
Cjoc42 is a compound capable of binding to gankyrin. Cjoc42 inhibits gankyrin activity in a dose-dependent manner. Cjoc42 prevents the decrease in p53 protein levels normally associated with high amounts of gankyrin. Cjoc42 restores p53-dependent transcription and sensitivity to DNA damage .
|
-
- HY-163329
-
|
Biochemical Assay Reagents
|
Neurological Disease
|
BCH-HSP-C01 is a lead compound that restores AP-4-dependent protein trafficking in neuronal models of adapter protein complex 4 (AP-4)-associated hereditary spastic paraplegia. BCH-HSP-C01 can be used for the research of autophagy-associated diseases .
|
-
- HY-157484
-
|
P-glycoprotein
|
Cancer
|
P-gp inhibitor 19 (Compound 6i) is a P-gp inhibitor. P-gp inhibitor 19 can inhibit the efflux of rhodamine 123 (HY-D0816) in P-gp-overexpressing leukemia cells K562/Dox and also restore the sensitivity of DOX-resistant cells .
|
-
- HY-132584
-
SRP-4045
|
Others
Dystrophin
|
Others
|
Casimersen (SRP-4045) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass. Casimersen binds to exon 45 of dystrophin pre-mRNA, restores the open-reading frame (by skipping exon 45) resulting in the production of an internally truncated but functional dystrophin protein. Casimersen can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
- HY-19980
-
APR-246; PRIMA-1Met
|
MDM-2/p53
Autophagy
Apoptosis
Ferroptosis
|
Cancer
|
Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance .
|
-
- HY-P991257
-
|
Interleukin Related
|
Cancer
|
MK-1966 is a humanized monoclonal antibody inhibitor targeting interleukin-10 (IL-10). MK-1966 blocks the inhibitory effects of IL-10 on immune cells such as macrophages and dendritic cells to restore anti-tumor immune responses. MK-1966 is promising for research of cancers .
|
-
- HY-162318A
-
|
Molecular Glues
c-Myc
|
Cancer
|
MYC degrader 1 TFA (compound A80.2HCl) is an orally available MYC molecular glues degrader with anti-tumor activity. MYC degrader 1 TFA restores pRB1 protein activity and re-establishes sensitivity of MYC overexpressing cancer cells to CDK4/6 inhibitors .
|
-
- HY-P2624A
-
|
PAK
|
Metabolic Disease
|
st-Ht31 ammonium is a membrane-permeable peptide inhibitor of?protein kinase A (PKA) anchoring. st-Ht31 ammonium induces robust cholesterol/phospholipid efflux. st-Ht31 ammonium completely reverses foam cell formation and restores the metabolic health of macrophage .
|
-
- HY-162258
-
|
Cholinesterase (ChE)
|
Neurological Disease
|
AChE-IN-57 (compound 5b(SP-2)) is a potent AChE inhibitor. AChE-IN-57 improves cognitive defects. AChE-IN-57 restores the biochemical mediators and inhibits reactive oxygen and nitrogen species implicated in the neuroinflammation mechanism. AChE-IN-57 has the potential for the research of Alzheimer .
|
-
- HY-B1804
-
Trioctanoin; Glyceryl trioctanoate
|
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
Tricaprilin (Trioctanoin) is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
- HY-105321R
-
PBT 2 (Standard)
|
Bacterial
|
Neurological Disease
|
PBT 1033 (Standard) is the analytical standard of PBT 1033. This product is intended for research and analytical applications. PBT 1033 (PBT 2) is an orally active copper/zinc ionophore. PBT 1033 restores cognition in mouse models of Alzheimer's disease (AD). PB 1033 also has antibacterial activity against Gram-positive bacteria .
|
-
- HY-102065
-
|
Prostaglandin Receptor
|
Others
|
SC-19220 is a competitive prostaglandinn E2 receptor antagonist. SC-19220 increases the bladder capacity and reduced the voiding efficiency of micturition (elicited by slow transvesical filling) of urethane-anesthetized rats. SC-19220 can restores the balance in bone marrow granulocyte and monocyte production after burn sepsis .
|
-
- HY-162837
-
|
Aurora Kinase
|
Cancer
|
AURKA against 1 is an inhibitor of AURKA (IC50 less than 0.5 nM), targeting endogenous lysine (K162) acetylation, and has anti-proliferation activity against tumor cells. AURKA against 1 induces K162 acetylation, and the kinase activity of AURKA is reversibly restored in HCT116 cells transfected with SIRT3 .
|
-
- HY-107355
-
|
Reactive Oxygen Species
|
Inflammation/Immunology
|
Letosteine is an orally active, potent and safe expectorant. Letosteine has the effect of scavenging reactive oxygen species (ROS). Letosteine dissolves bronchial mucus and reduces respiratory inflammation symptoms, and restores gas exchanges and natural defense mechanisms in the lung. Letosteine can be used for acute or chronic respiratory diseases (such as bronchopneumopathies) research .
|
-
- HY-12689
-
AG-348
|
Pyruvate Kinase
|
Metabolic Disease
|
Mitapivat (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency .
|
-
- HY-12689B
-
AG-348 hemisulfate
|
Pyruvate Kinase
|
Metabolic Disease
|
Mitapivat hemisulfate is an orally active pyruvate kinase allosteric activator. Mitapivat hemisulfate increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat hemisulfate can be used in study of PK deficiency .
|
-
- HY-14149A
-
R 51619 monohydrate; (±)-Cisaprid monohydrate
|
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
Cisapride monohydrate is an orally and potent 5-HT4 receptor agonist and hERG inhibitor. Cisapride monohydrate is an prokinetic agent which facilitates or restores motility throughout the length of the gastrointestinal tract. Cisapride monohydrate stimulates gastrointestinal motor activity through an indirect mechanism involving the release of acetylcholine mediated by postganglionic nerve endings in the myenteric plexus of the gut .
|
-
- HY-148698
-
|
VD/VDR
|
Others
|
2MD is an orally active vitamin D analog. 2MD stimulates periosteal bone formation and decreases trabecular bone resorption. Thus 2MD restores trabecular and cortical bone mass and strength. 2MD also regulates intraocular pressure (IOP)-relative genes and reduces IOP in non-human primates .
|
-
- HY-W104821
-
|
Keap1-Nrf2
|
Metabolic Disease
|
Rosolic Acid is an activator of Nrf2, as well as its downstream targets. Rosolic Acid increases the levels of angiogenic factors, decreases inflammation (TNF-α and IL-1β) and apoptotic markers (CXCL10 and CCL2). Rosolic Acid restores the function of pancreatic cells and protects endothelial cells (ECs) from endoplasmic reticulum stressed .
|
-
- HY-172786
-
|
Caspase
Apoptosis
|
Metabolic Disease
|
Caspase-3-IN-3 (compound 7) is a caspase 3 inhibitor. Caspase-3-IN-3 increases cellular ATP levels, inhibits caspase-3 activity, decreases nitrite production, suppresses cytokine-induced apoptosis, and restores Glucose (HY-B0389)-stimulated insulin secretion .
|
-
- HY-137817
-
|
DNA/RNA Synthesis
|
Metabolic Disease
|
BCH001, a quinoline derivative, is a specific PAPD5 inhibitor. BCH001 restores telomerase activity and telomere length in dyskeratosis congenita (DC) induced pluripotent stem cells. BCH001 shows no inhibition of poly(A)-specific ribonuclease (PARN) or several other canonical and non-canonical polynucleotide polymerases. BCH001 is used to regulate aging .
|
-
- HY-150089
-
|
CFTR
|
Inflammation/Immunology
|
SRI-37240 is a potent premature termination codons (PTCs) inhibitor. SRI-37240 suppresses CFTR nonsense mutations. SRI-37240 alters cellular translation termination at PTCs in HEK293T cells. SRI-37240 can also restore CFTR function in primary bronchial epithelial cells when combination with G418 .
|
-
- HY-117924
-
Autophagy enhancer-67
|
Autophagy
|
Neurological Disease
|
AUTEN-67 (Autophagy enhancer-67) is an orally active autophagy enhancer and MTMR14 inhibitor. AUTEN-67 has anti-aging and neuroprotective effects. AUTEN-67 protects neurons from stress-induced cell death. AUTEN-67 also restores nesting behavior in a mice model of Alzheimer disease .
|
-
- HY-136174
-
|
PARP
|
Cancer
|
RBN-2397 is a potent, accross species and orally active NAD + competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors .
|
-
- HY-123985
-
|
Mitochondrial Metabolism
|
Others
|
MFN2 agonist-1 (B-A/l) potently stimulates mitochondrial fusion in mitofusin 2 (MFN2)-deficient cells. MFN2 agonist-1 reverses mitochondrial “clumping” (formation of static mitochondrial aggregates) and restores mitochondrial motility in cultured mouse neurons expressing the CMT2A mutant MFN2 T105M.
|
-
- HY-101266A
-
DS-3032 tosylate
|
MDM-2/p53
|
Cancer
|
Milademetan tosylate is the tosylate salt form of Milademetan (HY-101266). Milademetan tosylate is an orally active inhibitor for MDM2. Milademetan tosylate arrests the cell cycle at G1 pahse, induces the apoptosis Milademetan tosylate restores the p53 activity by targeting the p53-MDM2 interaction, and exhibits anticancer activity against Merkel cell carcinoma (MCC) .
|
-
- HY-12689A
-
AG-348 hemisulfate sesquihydrate
|
Pyruvate Kinase
|
Metabolic Disease
|
Mitapivat hemisulfate sesquihydrate (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency .
|
-
- HY-N15315
-
|
Apoptosis
MAP3K
NF-κB
|
Others
|
Triptriolide inhibits Puromycin aminonucleoside PAN (HY-15695)-induced apoptosis in mouse podocytes through regulation of Bcl-2 family proteins and inhibition of Caspase-3. Triptriolide promotes the cell survival, protects and restores the podocyte function through activation of TAK1-NF-κB signaling pathway and upregulation of podocin .
|
-
- HY-114753
-
CR-2249; XY-2401
|
iGluR
|
Neurological Disease
|
Neboglamine (CR-2249; XY-2401) is a modulator for N-methyl-D-aspartate (NMDA) receptor. Neboglamine increases the levels of fos-like immunoreactivity (FLI)-positive cells in the prefrontal cortex, nucleus accumbens, and lateral septal nucleus in rat models, .restores NMDA (HY-17551) -mediated neurotransmitter release, and inhibits phencyclidine-induced hyperlocomotion .
|
-
- HY-B1074R
-
Etamsylate (Standard)
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
|
Ethamsylate (Standard) is the analytical standard of Ethamsylate. This product is intended for research and analytical applications. Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis. .
|
-
- HY-121503
-
|
Others
|
Neurological Disease
|
FD44 is a phenothiazine small molecule that inhibits the interaction between neuronal calcium sensor 1 (NCS-1) and the guanine exchange factor Ric8a, a key regulator of synapse number and neurotransmitter release probability. In the Drosophila genetic autism model of fragile X syndrome (FXS), FD44 restored normal synapse number and associative learning .
|
-
- HY-136234
-
|
Endogenous Metabolite
|
Others
|
9-cis-β-Carotene, a precursor of retinal, is cleaved by beta-carotene oxygenase 1 (BCMO1) to produce 9-cis-retinal. 9-cis-β-Carotene inhibits photoreceptor degeneration and restores retinal function in vivo. 9-cis-β-Carotene has the potential for the study of congenital stationary night blindness and fundus albipunctatus .
|
-
- HY-147149
-
|
Others
|
Neurological Disease
|
BPN-15477 is a potent SMC (splicing modulator compound) that restores correct splicing of ELP1 (Elongator complex protein 1) exon 20. BPN-15477 corrects splicing of the ELP1 transcript, significantly increases the level of functional protein in vivo in all tissues, including brain. BPN-15477 can be used for frontotemporal dementia research .
|
-
- HY-P3355
-
|
iGluR
|
Neurological Disease
|
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
|
-
- HY-119229
-
|
CFTR
|
Others
|
VRT-325 is a novel small molecule discovered by screening a compound library designed to address the genetic defect in cystic fibrosis (CF) caused by the ΔF508 mutation in CFTR. VRT-325 belongs to a class of compounds that promote ΔF508-CFTR efflux from the endoplasmic reticulum and restores chloride transport levels in epithelial cells of CF-derived bronchi .
|
-
- HY-132586A
-
NS-065/NCNP-01 sodium
|
Nucleoside Antimetabolite/Analog
Dystrophin
|
Metabolic Disease
|
Viltolarsen (NS-065/NCNP-01) sodium is a phosphorodiamidate morpholino antisense oligonucleotide. Viltolarsen sodium binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. Viltolarsen sodium has the potential for Duchenne muscular dystrophy (DMD) research .
|
-
- HY-172907
-
|
Dengue Virus
|
Infection
|
SMU-1k is a highly effective and broad-spectrum antiviral agent. SMU-1k inhibits ZIKV and DENV-2 with EC50s of 7.08 and 3.96 μM, respectively. SMU-1k significantly inhibits NS5 protein expression and restores the level of STAT2 .
|
-
- HY-P10950
-
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers .
|
-
- HY-132586
-
NS-065/NCNP-01
|
Nucleoside Antimetabolite/Analog
Dystrophin
|
Metabolic Disease
|
Viltolarsen (NS-065/NCNP-01) is a phosphorodiamidate morpholino antisense oligonucleotide. Viltolarsen binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. Viltolarsen has the potential for Duchenne muscular dystrophy (DMD) research .
|
-
- HY-110135
-
|
IGF-1R
|
Neurological Disease
Inflammation/Immunology
|
NBI-31772 is a non-selective IGFBP inhibitor (Ki=47 nM). NBI-31772 has neuroprotective effects and reduces infarct volume during cerebral ischemia. NBI-31772 can also restore or enhance proteoglycan synthesis in osteoarticular chondrocytes. In addition, NBI-31772 also increases the effect of IGF3 on zebrafish oocyte maturation .
|
-
- HY-153480
-
BAX499
|
Factor Xa
Factor VIIa
Tissue Factor Pathway Inhibitor (TFPI)
|
Others
|
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
|
-
- HY-153480A
-
BAX499 sodium
|
Factor Xa
Factor VIIa
Tissue Factor Pathway Inhibitor (TFPI)
|
Others
|
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
|
-
- HY-171454
-
|
GPR119
|
Metabolic Disease
Inflammation/Immunology
|
DA-1241 is a GPR119 agonist. DA-1241 reduces macrophage differentiation through downregulation of NFκB signaling by activating GPR119. DA-1241, alone and in combination with a DPP4 inhibitor, reduces liver inflammation and restores inflammation-related liver gene expression. DA-1241 can be used for the research of metabolic dysfunction-associated steatohepatitis (MASH) .
|
-
- HY-151389
-
|
Cholinesterase (ChE)
|
Neurological Disease
|
BChE-IN-14 (compound 19c) is a selective butyrylcholinesterase (BChE) inhibitor with IC50s of 0.23 and 0.011 μM for eqBChE and hBChE, respectively. BChE-IN-14 shows good blood brain barrier permeation and primary cell safety. BChE-IN-14 is able to restore cognitive impairment in vivo, it can be used for the research of Alzheimer’s disease .
|
-
- HY-173453
-
|
Aldose Reductase
Apoptosis
|
Cancer
|
AKR1C3-IN-15 (compound 30) is a potent and selective AKR1C3 inhibitor with an IC50 of 5 nM. AKR1C3-IN-15 enhances Sorafenib (HY-10201)-induced ROS generation, promoted apoptosis, and restored sorafenib sensitivity in HCC models both in vitro and in vivo .
|
-
- HY-135741
-
|
iGluR
|
Neurological Disease
|
NYX-2925 is an orally active NMDAR modulator. NYX-2925 restores levels of activated Src and Src phosphorylation sites on GluN2A and GluN2B in the mPFC. NYX-2925 shows no effect on CAMKII, and any addictive or sedative/ataxic side effects. NYX-2925 can be used for research of a variety of NMDA receptor-mediated central nervous system disorders .
|
-
- HY-155572
-
|
Keap1-Nrf2
|
Inflammation/Immunology
|
Nrf2 activator-8 (compound 10e) is a Nrf2 activator (EC50=37.9 nM). Nrf2 activator-8 exhibits remarkable antioxidant and anti-inflammatory effects in BV-2 microglial cells. Nrf2 activator-8 can significantly restore spatial memory deficits in a mouse model of lipopolysaccharide (LPS)-induced neuroinflammation .
|
-
- HY-105416
-
UCN-1028C
|
Antibiotic
PKC
Apoptosis
|
Metabolic Disease
Cancer
|
Calphostin C is a highly selective PKC inhibitor (IC50=0.05 μM) and tumor apoptosis inducer. Calphostin C competitively binds to PKC and inhibits PKC-mediated phosphorylation signal transduction. Calphostin C restores Na+/K+ ATPase activity in the sciatic nerve of diabetic mice and improves neuropathy. Calphostin C can be used in the study of anti-tumor and diabetic complications .
|
-
- HY-N7140R
-
γ-Linolenic acid (Standard)
|
Endogenous Metabolite
|
Metabolic Disease
|
Gamma-Linolenic acid (Standard) is the analytical standard of Gamma-Linolenic acid. This product is intended for research and analytical applications. Gamma-linolenic acid (γ-Linolenic acid) is an omega-6 (n-6), 18 carbon (18C-) polyunsaturated fatty acid (PUFA) extracted from Perilla frutescens. Gamma-linolenic acid supplements could restore needed PUFAs and mitigate the disease .
|
-
- HY-156633
-
PC14586
|
MDM-2/p53
|
Cancer
|
Rezatapopt (PC14586) is an orally active antineoplastic agent. Rezatapopt binds to a pocket created by the TP53 Y220C mutation. Rezatapopt restores p53 tumor suppressor functions by stabilization of the p53 protein structure. Rezatapopt demonstrates tumor inhibition and regression in mouse models with established human tumor xenografts harboring the TP53 Y220C mutation .
|
-
- HY-18669
-
ML346
5 Publications Verification
|
HSP
|
Cancer
|
ML346 is an activator of Hsp70 expression and HSF-1 activity, with an EC50 of 4.6 μM for Hsp70. ML346 restores protein folding in conformational disease models, without significant cytotoxicity or lack of specificity. ML346 induces specific increases in genes and protein effectors of the heat shock response (HSR), including chaperones such as Hsp70, Hsp40, and Hsp27 .
|
-
- HY-155687
-
|
Phosphodiesterase (PDE)
|
Neurological Disease
|
PDE5-IN-10 (compound 4b) is a potent PDE5 inhibitor with an IC50 of 20 nM. PDE5-IN-10 improves in vitro microsomal stability (t1/2 = 44.6 min) as well as excellent efficacy in restoring long-term potentiation. PDE5-IN-10 can be used for Alzheimer’s disease (AD) research .
|
-
- HY-125146
-
|
Wnt
|
Others
|
BMD4503-2 is a quinoxaline derivative with inhibitory activity against LRP5/6-sclerostin interactions. BMD4503-2 restores the activity of the Wnt/β-catenin signaling pathway by competitively binding to the LRP5/6-sclerostin complex. BMD4503-2 can be used in the study of Wnt signaling pathways in bone development, maintenance and osteoporosis .
|
-
- HY-P99590
-
ACE-011
|
TGF-β Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
|
-
- HY-122282
-
|
Angiotensin Receptor
|
Cardiovascular Disease
|
AZ11657312 is a P2X7 receptor antagonist with activity to restore stress natriuresis. AZ11657312 significantly increased renal medullary perfusion, only in mice treated with angiotensin II. AZ11657312 improves tissue oxygenation by blocking P2X7R, especially in areas of the kidney that are underoxygenated. Administration of AZ11657312 increased sodium excretion up to sixfold while normalizing blood pressure .
|
-
- HY-157440
-
|
Amyloid-β
Reactive Oxygen Species
Cholinesterase (ChE)
|
Neurological Disease
|
AChE/Aβ-IN-3 (compound AM5) is a dual inhibitor of AChE and Amyloid-β aggregation with IC50<.sub> values of 1.29 and 4.93 μM, respectively. AChE/Aβ-IN-3 has antioxidant properties that scavenge ROS and restore their normal levels. AChE/Aβ-IN-3 can be used in the study of neurological diseases, such as Alzheimer's disease .
|
-
- HY-170794
-
|
Acyltransferase
|
Metabolic Disease
|
ALT-007 is an orally effective serine palmitoyltransferase (SPT) inhibitor. SPT is the rate-limiting enzyme for the de novo synthesis of ceramide. In a mouse model of age-related sarcopenia, ALT-007 can effectively restore the muscle mass and function impaired by aging. ALT-007 may enhance protein homeostasis in Caenorhabditis elegans and mouse models of aging and age-related diseases and play the role of a ceramide inhibitor .
|
-
- HY-B1331
-
Cyromazin; CGA-72662
|
Endogenous Metabolite
Parasite
|
Neurological Disease
Metabolic Disease
|
Cyromazine (CGA-72662) is a triazine insect growth regulator used as an insecticide and an acaricide. It is a cyclopropyl derivative of melamine. Cyromazine works by affecting the nervous system of the immature larval stages of certain insects. Cyromazine reduced the number of germ cells by interfering with the Ecdysone (HY-N0179) signaling pathway. Cyromazine induces renal toxicity attenuated and restored by green tea extract in rats .
|
-
- HY-173290
-
|
Phosphodiesterase (PDE)
Interleukin Related
CXCR
TNF Receptor
|
Inflammation/Immunology
|
PDE4-IN-1 is a PDE4 inhibitor with high potency (IC50 : 8.6 nM) and selectivity over other PDE subtypes. PDE4-IN-1 inhibits the release of inflammatory cytokines and chemokines. PDE4-IN-1 greatly restores impaired cAMP-CREB signaling pathway. PDE4-IN-1 inhibits proliferation and promotes differentiation to reverse the formation of psoriasis .
|
-
- HY-B1804S2
-
Trioctanoin-d15; Glyceryl trioctanoate-d15
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
Tricaprilin-d15 (Trioctanoin-d15) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
- HY-139577
-
IMB-1018972; IMB-101
|
Mitochondrial Metabolism
|
Cardiovascular Disease
Metabolic Disease
|
Ninerafaxstat (IMB-1018972) is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat can be used for research on cardiovascular diseases .
|
-
- HY-B1804S1
-
Trioctanoin-d50; Glyceryl trioctanoate-d50
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
Tricaprilin-d50 (Trioctanoin-d50) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
- HY-150565
-
|
P-glycoprotein
|
Cancer
|
P-gp inhibitor 5 is a potent P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 5 has antiproliferative activity against certain cancer cell lines. P-gp inhibitor 5 is effective in reversing the multidrug resistance (MDR) phenotype in ABCB1/Flp-In TM-293 and KBvin cells by restoring their sensitivity to Vincristine (HY-N0488A) and Paclitaxel (HY-B0015) .
|
-
- HY-112671
-
RTA dh404
|
Keap1-Nrf2
NF-κB
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
|
CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB . CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats .
|
-
- HY-P10439
-
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a KD of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research .
|
-
- HY-N6804
-
|
NF-κB
Reactive Oxygen Species
|
Inflammation/Immunology
Cancer
|
Diammonium glycyrrhizinate is a substance that can be extracted and purified from a traditional Chinese medicinal herb. Diammonium glycyrrhizinate has anti-inflammatory effect, resistance to biologic oxidation, membranous protection and a weak steroidal action. Diammonium glycyrrhizinate exerts protective effect by downregulating inflammation cytokines, suppressing the NF-κB pathway, and restoring superoxide dismutase. Diammonium glycyrrhizinate can be used as a hepatic protector and can therefore be studied in research for most liver diseases .
|
-
- HY-145785
-
|
MDM-2/p53
Apoptosis
|
Cancer
|
ADH-6 is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 has the potential for the research of cancer diseases[1].
|
-
- HY-110143
-
|
Potassium Channel
|
Neurological Disease
|
CLP257 is a selective K +-Cl cotransporter KCC2 activator with an EC50 of 616 nM. CLP257 is inactive against NKCC1, GABAA receptors, KCC1, KCC3 or KCC4. CLP257 restores impaired Cl transport in neurons with diminished KCC2 activity. CLP257 alleviates hypersensitivity in rats with neuropathic pain. CLP257 modulates plasmalemmal KCC2 protein turnover post-translationally .
|
-
- HY-D1590
-
|
Fluorescent Dye
|
Others
|
ODIPY Green 8-P2M is a novel thiol-reactive fluorescence probe based on the BODIPY fluorophore, the fluorescence is strongly quenched by d-PeT and then can be restored after reaction with thiol, resulting in an extremely high signal-to-noise ratio. ODIPY Green 8-P2M can be useful for detecting extremely low concentrations of protein in the gel after SDS-PAGE .
|
-
- HY-111782
-
8-Thioguanosine
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
8-Mercaptoguanosine is an immunoadjuvant that affects the in vivo antibody response to the T-cell-independent antigen TNP-Ficoll. 8-Mercaptoguanosine enhances IgG1, IgG2, and IgG3 antibody responses, but has no effect on IgM antibody responses. 8-Mercaptoguanosine also enhances antibody responses to very weak antigens such as pneumococcal polysaccharide and restores antibody responses in immunodeficient xid mice that are non-reactive to TNP-Ficoll .
|
-
- HY-19980G
-
APR-246; PRIMA-1Met
|
MDM-2/p53
Apoptosis
Ferroptosis
|
Cancer
|
Eprenetapopt (GMP) (APR-246(GMP)) is Eprenetapopt (HY-19980) in GMP grade. Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance .
|
-
- HY-N0321
-
trans-Caftaric acid
|
Others
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Caftaric acid (trans-Caftaric acid) is a polyphenolic antidiuretic, antioxidant and anti-apoptotic agent that can be hydrolyzed by intestinal microbial esterases. Caftaric acid exerts its antioxidant and potential anti-inflammatory effects mainly through intestinal microbial metabolism. Caftaric acid can reduce renal damage, restore electrolyte balance, renal function indicators and antioxidant enzyme activities in a rat albinism model, and further exert anti-oxidative stress and anti-inflammatory activities .
|
-
- HY-P3354
-
|
iGluR
|
Neurological Disease
|
p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
|
-
- HY-131944
-
|
Apoptosis
HSV
|
Infection
Cancer
|
S-Acetylglutathione is a derivative of Glutathione (HY-D0187). S-Acetylglutathione is stable in blood, and can be converted to glutathione by intracellular thioesterases. S-Acetylglutathione restores the intracellular glutathione content in glutathione synthetase deficient fibroblasts. S-Acetylglutathione exhibits antiviral efficacy in HSV-1 infected model through inhibition of viral replication. S-Acetylglutathione induces apoptosis in cancer cells MOLT4 and UKF-NB-3 .
|
-
- HY-145917
-
|
Toll-like Receptor (TLR)
|
Neurological Disease
|
SARM1-IN-2 (Example 82) is a SARM1 inhibitor (IC50 <1 μM) that inhibits axon regeneration. Axon regeneration refers to the process by which neuronal axons attempt to restore their structure and function after axonal degeneration. SARM1-IN-2 inhibits axon regeneration by reducing or inhibiting the binding of SARM1 to NAD+. SARM1-IN-2 can be used to study axonal degeneration .
|
-
- HY-160062
-
|
Mucin
|
Cancer
|
S2.2 aptamer sodium is a nucleic acid aptamer targeting the mucin MUC1 and can be used for targeted imaging of MCF-7 cancer cells. S2.2 aptamer sodium was labeled with Cy5, and when fluorescent silicon nanodots (SiND) were present, the fluorescence was quenched; when MUC1 was also present, the fluorescence was restored. S2.2 aptamer sodium detects MUC1 with a linear range of 3.33-250 nM .
|
-
- HY-156085
-
|
PD-1/PD-L1
|
Cancer
|
LP23 is a non-arylmethylamine PD-1/PD-L1 inhibitor (IC50: 16.7 nM) with anti-tumor activity. LP23 restores immune cell function in HepG2/Jurkat T cells and promotes HepG2 cell death. LP23 is active in vivo in the B16-F10 tumor model (TGI=88.6% at 30 mg/kg) .
|
-
- HY-P991443
-
|
CD73
|
Cancer
|
IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-163719
-
|
PARP
|
Cancer
|
PARP7-IN-22 (XLY-1) is a PARP7 inhibitor with an IC50 of 0.6 nM. PARP7-IN-22 (XLY-1) is orally active, enhances type I interferon signaling in vitro, restores type I interferon signaling, promotes T cell infiltration into tumor tissues, and significantly inhibits tumor growth. PARP7-IN-22 shows promise for research in the field of cancer immunotherapy .
|
-
- HY-159146
-
-
- HY-145785A
-
|
MDM-2/p53
Apoptosis
|
Cancer
|
ADH-6 TFA is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 TFA targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 TFA has the potential for the research of cancer diseases .
|
-
- HY-111520
-
|
DNA/RNA Synthesis
|
Neurological Disease
|
NVS-SM2 is a potent, orally active and brain-penetrant SMN2 splicing enhancer with an EC50 of 2 nM for SMN. NVS-SM2 enhances U1-pre-mRNA association. NVS-SM2 promotes exon 7 inclusion and restores normal survival motor neuron (SMN) protein expression. NVS-SM2 can be used for spinal muscular atrophy (SMA) research .
|
-
- HY-170509
-
|
Ferroptosis
Glutathione Peroxidase
|
Cardiovascular Disease
Neurological Disease
Cancer
|
Ferroptosis-IN-17 (Compound 18) is a ferroptosis (Ferroptosis) inhibitor with an EC50 value of 0.57 μM. Ferroptosis-IN-17 reduces intracellular ferrous ion accumulation, lipid peroxidation, and effectively restores the levels of glutathione (GSH) and glutathione peroxidase 4 (GPX4). Ferroptosis-IN-17 shows good solubility and significant metabolic stability in rat plasma. Ferroptosis-IN-17 is promising for research in tumor suppression, neurodegenerative diseases, and cardiovascular diseases .
|
-
- HY-150090
-
|
CFTR
|
Inflammation/Immunology
|
SRI-41315 induces a prolonged pause at stop codons and suppresses PTCs (premature termination codons) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR (cystic fibrosis transmembrane conductance regulator) expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity .
|
-
- HY-134050
-
Apt-1
|
RIP kinase
Autophagy
Apoptosis
Beclin1
Necroptosis
|
Inflammation/Immunology
|
Apostatin-1 (Apt-1) is a potent TRADD inhibitor. Apostatin-1 can bind with TRADD-N (KD=2.17 μM), disrupting its binding to both TRADD-C and TRAF2. Apostatin-1 modulates the ubiquitination of RIPK1 and beclin 1. Apostatin-1 blocks apoptosis and restores cellular homeostasis by activating autophagy in cells with accumulated mutant tau, α-synuclein, or huntingtin .
|
-
- HY-110088
-
|
MDM-2/p53
|
Cancer
|
SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a Ki of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .
|
-
- HY-161321
-
|
Phosphatase
Insulin Receptor
Akt
|
Metabolic Disease
|
PTP1B-IN-24 (Compound 9) is a reversible PTP1B inhibitor with an IC50 value of 1.4 μM, and PTP1B-IN-24 can enhance the thermal stability of PTP1B. PTP1B-IN-24 can restore PA- (HY-N0830) induced insulin resistance by increasing the phosphorylation levels of IRS1 and AKT .
|
-
- HY-N4095
-
|
Aryl Hydrocarbon Receptor
Glycosidase
Reactive Oxygen Species
GLUT
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Brevifolincarboxylic acid is a phenolic compound. Brevifolincarboxylic acid can be isolated from Duchesnea chrysantha. Brevifolincarboxylic acid inhibits α-glucosidase with an IC50 value of 323.46 μM. Brevifolincarboxylic acid has an inhibitory effect on the aryl hydrocarbon receptor (AhR). Brevifolincarbacid scavenges ROS. Brevifolincarbacid restores the glucose uptake activity of myotubes. Brevifolincarboxylic acid has antitumor activity against lung and gastric cancer. Brevifolincarbacid can be used in the study of diabetes and inflammatory diseases .
|
-
- HY-P991440
-
|
TNF Receptor
|
Inflammation/Immunology
|
AMG-966 is a human bispecific antibody (bsAb) targeting TNFSF15/TL1A & TNFα. AMG 966 restores the ability of the aglycosylated Fc domain to bind to FcγRIa and FcγRIIa, leading to the formation of antidrug antibodies (ADA). AMG-966 can be used in Crohn's disease and Ulcerative colitis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-N13218
-
|
Others
|
Cardiovascular Disease
|
Pueraria Extract is a kudzu extract, and its components include: Isoflavones. Pueraria Extract (ethanol extract) can significantly improve cardiac damage in rats with acute myocardial infarction. Pueraria Extract improves bile acid levels by increasing the expression of CYP7A1 and restoring the diversity of intestinal microbiota. Pueraria Extract can also inhibit the FXR-FGF15 signaling pathway and increase the expression of OST-α to increase bile acid reabsorption and fecal excretion. .
|
-
- HY-B1804S
-
Trioctanoin-13C3; Glyceryl trioctanoate-13C3
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
Tricaprilin- 13C3 (Trioctanoin- 13C3) is a 13C-labeled Tricaprilin (HY-B1804) . Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
- HY-162566
-
|
Calcium Channel
Amyloid-β
|
Neurological Disease
|
REM127 is a small molecule compound capable of modulating calcium homeostasis in cells and possesses neuroprotective effects. REM127 can restore the calcium homeostasis imbalance in cellular models caused by pathological accumulation of tau protein. REM127 can efficiently cross the blood-brain barrier, and it has the potential to rescue synaptic and cognitive deficits in Alzheimer's disease animal models, as well as to slow down the progression of amyloid-beta and tau protein pathologies. REM127 can be used for research in neurodegenerative diseases .
|
-
- HY-162000
-
|
Apoptosis
|
Cancer
|
hCAIX/XII-IN-13 is an inhibitor of human carbonic anhydrases (hCA). hCAIX/XII-IN-13 shows good inhibitory activity against the tumor-related CA subtypes IX and XII, with Ki values of 0.08 µM and 0.06 µM, respectively. Under hypoxic conditions, hCAIX/XII-IN-13 can restore the cytotoxicity of Doxorubicin (HY-15142A) on MCF-7 cells, increasing G2/M phase cell cycle arrest and apoptosis .
|
-
- HY-B1218
-
|
Cytochrome P450
Antibiotic
Bacterial
Necroptosis
Apoptosis
|
Infection
Cardiovascular Disease
|
Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion .
|
-
- HY-N9182
-
Physalien
|
Adiponectin Receptor
P2X Receptor
Autophagy
|
Inflammation/Immunology
|
Zeaxanthin dipalmitate (Physalien) is a wolfberry-derived carotenoid, has anti-inflammatory and anti-oxidative stress effects. Zeaxanthin dipalmitate directly interact with p2X7 receptor (Kd=81.2 nM) and adiponectin receptor 1 (AdipoR1; Kd=533 nM) in a positive dose-dependent manner. Zeaxanthin dipalmitate restores mitochondrial autophagy functions suppressed by ethanol intoxication. Zeaxanthin dipalmitate can be used in the research of alcoholic fatty liver disease (AFLD) and retinitis pigmentosa (RP) .
|
-
- HY-B1331R
-
|
Endogenous Metabolite
Parasite
|
Neurological Disease
Metabolic Disease
|
Cyromazine (Standard) is the analytical standard of Cyromazine. This product is intended for research and analytical applications. Cyromazine (CGA-72662) is a triazine insect growth regulator used as an insecticide and an acaricide. It is a cyclopropyl derivative of melamine. Cyromazine works by affecting the nervous system of the immature larval stages of certain insects. Cyromazine reduced the number of germ cells by interfering with the Ecdysone (HY-N0179) signaling pathway. Cyromazine induces renal toxicity attenuated and restored by green tea extract in rats .
|
-
- HY-153202
-
|
MDM-2/p53
Apoptosis
|
Cancer
|
SLMP53-2 is a mutant p53 reactivator. SLMP53-2 restores wild-type-like conformation and DNA-binding ability of mutp53-Y220C by enhancing its interaction with the Hsp70, leading to the reestablishment of p53 transcriptional activity. SLMP53-2 can induce cell cycle arrest, apoptosis and endoplasmic reticulum (ER) stress. SLMP53-2 exhibits antitumor activity .
|
-
- HY-148404
-
|
MDM-2/p53
|
Cancer
|
p53 Activator 5 (compound 134A) is a potent p53 activator with a SC150 value of <0.05 mM. p53 Activator 5 can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA. p53 Activator 5 shows anti-tumor activity . p53 Activator 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-144649
-
|
PD-1/PD-L1
|
Cancer
|
PD-1/PD-L1-IN-24 is a highly potent PD-1/PD-L1 inhibitor with IC50 value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs .
|
-
- HY-139577A
-
MB-1018972 trihydrochloride; IMB-101 trihydrochloride
|
Mitochondrial Metabolism
|
Cardiovascular Disease
Metabolic Disease
|
Ninerafaxstat trihydrochloride (IMB-1018972 trihydrochloride) is the trihydrochloride salt form of Ninerafaxstat (HY-139577). Ninerafaxstat trihydrochloride is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat trihydrochloride competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat trihydrochloride can be used for research on cardiovascular diseases .
|
-
- HY-N11997
-
|
Cholinesterase (ChE)
|
Neurological Disease
|
Feralolide is a dihydroisocoumarin isolated from the methanolic extract of aloe vera resin. Feralolide is also a dual inhibitor of AChE and BuChE, with IC50s of 55 μg/mL and 52 μg/mL respectively. Feralolide has antioxidant activity and inhibits 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2, 2′-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS). Feralolide could be used in research into cognitive disorders such as Alzheimer's disease, potentially restoring and enhancing memory .
|
-
- HY-125662A
-
|
Reactive Oxygen Species
Apoptosis
|
Metabolic Disease
|
BMX-001, a novel redox-active metalloporphyrin, improves islet function and engraftment in a murine transplant model. BMX-001 reduces apoptosis in human and murine islets. BMX-001 significantly improves static-glucose stimulated insulin secretion (sGSIS) responses in murine islets. BMX-001 can significantly restore euglycemia in murine islet studies in the presence of the MnSOD. BMX-001 reduces the generation of ROS in a murine islet isolation and culture model .
|
-
- HY-148402
-
|
MDM-2/p53
|
Cancer
|
p53 Activator 3 (compound 87A) is a potent p53 activator with a SC150 value of <0.05 mM. p53 Activator 3 can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA. p53 Activator 3 shows anti-tumor activity . p53 Activator 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-107719
-
|
iGluR
|
Neurological Disease
|
D-AP7 is a specific NMDA receptor antagonist with inhibitory activity against epileptiform activity. D-AP7 attenuated neuronal activation in spot activity by reducing the duration and number of exogenously induced bursts. D-AP7 also increased the amplitude of secondary action potentials, which may restore neuronal activity in some epileptiform bursts. D-AP7 showed anxiogenic effects and impaired memory consolidation in passive avoidance learning .
|
-
- HY-119196
-
SP-233
|
Amyloid-β
Sigma Receptor
|
Others
|
Caprospinol (SP-233) is a steroid compound candidate based on the structure of 22R-hydroxycholesterol. It has multiple mechanisms of neuroprotection, including binding to β-amyloid protein (Aβ(42)), interacting with the mitochondrial respiratory chain, clearing Aβ(42) monomers, and acting as a σ-1 receptor ligand. It can cross the blood-brain barrier in vivo and restore cognitive impairment, and has the potential to inhibit Alzheimer's disease.
|
-
- HY-161940
-
|
PCSK9
|
Cardiovascular Disease
|
PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC50 = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases .
|
-
- HY-132828
-
LT3001; DHDMIQK(KAP)
|
P-selectin
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities .
|
-
- HY-P991441
-
|
TREM receptor
Apoptosis
|
Neurological Disease
|
VGL101 is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. VGL101 is a pSYK agonist (EC50: 0.77 nM). VGL101 restores the survival ability of microglia and monocyte-derived macrophages under ALSP pathological conditions, inhibits apoptosis, and promotes the restoration of cell morphology to a state similar to that of normal activated CSF1R. VGL101 can be used in Leukoencephalopathies research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-148416
-
|
MDM-2/p53
|
Cancer
|
p53 Activator 7 is a p53 mutation Y220C (MDM-2/p53) activator with an EC50 of 104 nM. p53 Activator 7 can bind to p53 mutant and restore its ability to bind DNA (WO2022213975A1; Example B-1) . p53 Activator 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-158030
-
|
HDAC
|
Neurological Disease
|
HDAC6-IN-37 (compound W5) is an inhibitor of HDAC6 and has neuroprotective effects. HDAC6-IN-37 can restore the morphology of hippocampal neurons, reduce the expression of Aβ, Tau, and p-Tau proteins in the hippocampus of AD rats, and inhibit the formation of senile plaques and neurofibrillary tangles. Thus, HDAC6-IN-37 improves the Aβ/Cu 2+-induced AD model in rats, regulates oxidative stress status, and balances neurotransmitter disorders in brain tissue .
|
-
- HY-P3736
-
MP-2
|
Interleukin Related
|
Cancer
|
Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research .
|
-
- HY-P10404
-
|
α-synuclein
|
Others
Neurological Disease
|
PDpep1.3 is a peptide inhibitor of α-synuclein that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions .
|
-
- HY-101259
-
-
- HY-169021
-
|
JNK
|
Cancer
|
JNK-1-IN-3 (Compound 9e) is an inhibitor of JNK1 that downregulates JNK1 gene expression and inhibits the protein levels of its phosphorylated form, concurrently reducing the expression of its downstream targets, c-Jun and c-Fos, in tumors while restoring p53 activity. JNK-1-IN-3 exhibits broad-spectrum antiproliferative activity, particularly with high inhibitory activity against renal and breast cancer cell lines, demonstrating both in vivo and in vitro anticancer activity .
|
-
- HY-172941
-
|
NOD-like Receptor (NLR)
|
Neurological Disease
|
VEN-02XX is an orally active and brain-permeable NLRP3 inhibitor. VEN-02XX inhibits the release of IL-1β and IL-18 (IC50 0.3 and 0.28 μM, respectively). VEN-02XX restores memory and cognition, inhibits microgliosis, and reduces neuroinflammation and tau pathology in the 5XFAD/Rubicon KO mouse model. VEN-02XX may be used in the study of Alzheimer's disease (AD) .
|
-
- HY-162644
-
|
PD-1/PD-L1
PARP
|
Cancer
|
Antitumor agent-170 (Compound C6) exhibits inhibitory activities against PD-1/PD-L1 interaction and PARP7, with IC50 of 0.342 μM and 7.05 nM. Antitumor agent-170 exhibits a high affinity to human PD-L1, with a Ki of 9.31 nM. Antitumor agent-170 restores the T cell function and increases IFN-γ secretion. Antitumor agent-170 exhibits antitumor efficacy against melanoma in mouse models and good pharmacokinetic characteristics .
|
-
- HY-16468
-
MSI-1256
|
Bacterial
HBV
FAK
Dengue Virus
|
Infection
Neurological Disease
Cancer
|
Squalamine (MSI-1256) is an aminosterol compound with broad-spectrum antiviral activity. Squalamine makes cells less conducive to certain viral replication by altering the electrostatic interactions in the inner membrane of host cells. Squalamine also has antibacterial and antitumor activities. Squalamine has broad-spectrum antibacterial activity against Gram-negative and Gram-positive bacteria, fungi and protozoa. Squalamine inhibits tumor-related angiogenesis and the growth of human breast cancer cells. Squalamine restores the function of enteric nervous system in Parkinson ,s disease mouse models .
|
-
- HY-147041
-
GB1211
|
Galectin
|
Inflammation/Immunology
Cancer
|
Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC50 value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen). Selvigaltin restores T-cell activity and induces less tumors and metastasis .
|
-
- HY-N4095R
-
|
Aryl Hydrocarbon Receptor
Glycosidase
Reactive Oxygen Species
GLUT
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Brevifolincarboxylic acid (Standard) is the analytical standard of Brevifolincarboxylic acid (HY-N4095). This product is intended for research and analytical applications. Brevifolincarboxylic acid is a phenolic compound. Brevifolincarboxylic acid can be isolated from Duchesnea chrysantha. Brevifolincarboxylic acid inhibits α-glucosidase with an IC50 value of 323.46 μM. Brevifolincarboxylic acid has an inhibitory effect on the aryl hydrocarbon receptor (AhR). Brevifolincarbacid scavenges ROS. Brevifolincarbacid restores the glucose uptake activity of myotubes. Brevifolincarboxylic acid has antitumor activity against lung and gastric cancer. Brevifolincarbacid can be used in the study of diabetes and inflammatory diseases .
|
-
- HY-P99431
-
Alomfilimab; SAR 445256
|
CD28
|
Inflammation/Immunology
Cancer
|
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 + TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
|
-
- HY-163345
-
|
5-HT Receptor
|
Neurological Disease
|
5-HT7R antagonist 2 (compound 4h) is a 5-HT7R antagonist that antagonizes the G protein and β-arrestin signaling pathways, with a Ki of 67 nM, the IC50 values in cAMP and Tango tests were 2.59 μM and 39.57 μM, respectively. 5-HT7R antagonist 2 has an effect on neurogenesis and can reduce repetitive behaviors related to autism spectrum disorder (ASD) and restore neurogenesis of ASD impairment .
|
-
- HY-122144
-
Teroxirone
|
Endogenous Metabolite
|
Cancer
|
α-Triglycidyl isocyanurate (Teroxirone) is an antitumor compound with activity to inhibit DNA replication. α-Triglycidyl isocyanurate exerts its anticancer effect by alkylating and cross-linking DNA. α-Triglycidyl isocyanurate is relatively stable in fresh human plasma and whole blood, showing good biocompatibility. The metabolism of α-Triglycidyl isocyanurate mainly occurs in rat liver and is metabolized through an NADPH-independent pathway. The cytotoxicity of α-Triglycidyl isocyanurate can be partially restored under specific conditions, suggesting the complexity of its metabolic pathway .
|
-
- HY-10965
-
KW-3902
|
Adenosine Receptor
|
Neurological Disease
|
Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment.
Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) .
Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .
|
-
- HY-B1218R
-
|
Cytochrome P450
Antibiotic
Bacterial
Necroptosis
Apoptosis
|
Infection
Cardiovascular Disease
|
Sulfaphenazole (Standard) is the analytical standard of Sulfaphenazole. This product is intended for research and analytical applications. Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion .
|
-
- HY-170948
-
|
Adenosine Receptor
|
Cancer
|
A2AR modulator-1 (Compound 45) is a selective negative allosteric adenosine A2a receptor (A2aR) modulator with an IC50 value of 9 nM. A2AR modulator-1 reduces the affinity of endogenous adenosine for the receptor and inhibits cAMP signaling pathway activation. A2AR modulator-1 potently restores pCREB phosphorylation in CD4 + T cells, reversing immunosuppression in the tumor microenvironment, and shows potential to suppress tumor growth and metastasis in triple-negative breast cancer models .
|
-
- HY-150260
-
|
Bacterial
|
Infection
|
SA09-Cu is a noncompetitive and potent NDM-1 inhibitor with an IC50 of 9.6 nM. SA09-Cu can convert NDM-1 into an inactive state by oxidizing the Zn(II)-thiolate site of the enzyme and avoids to be reduced by intracellular thiols of bacteria. SA09-Cu exhibits excellent inhibition against a series of clinical NDM-1-producing carbapenem-resistant Enterobacteriaceae (CRE) in restoring the Meropenem (HY-13678) effect, and slows down the development of carbapenem resistance .
|
-
- HY-173371
-
|
Phospholipase
|
Neurological Disease
|
BRI-50460 is an inhibitor of cytosolic calcium-dependent phospholipase A2 (cPLA2) that has the ability to penetrate the blood-brain barrier, with an IC50 of 0.88 nM. BRI-50460 exerts the activities of regulating neuroinflammation and restoring lipid homeostasis by inhibiting cPLA2, regulating the downstream inflammatory lipid signaling pathway, and alleviating the effects of amyloid β42 oligomers on the activation of cPLA2, the hyperphosphorylation of tau protein, and the reduction of synapses and dendrites. BRI-50460 can be applied to the research in the fields of Alzheimer's disease and other neurodegenerative diseases .
|
-
- HY-133910
-
|
Sodium Channel
|
Neurological Disease
|
Lu AE98134, an activator of voltage-gated sodium channels, acts as a partly selective Nav1.1 channels positive modulator. Lu AE98134 also increases the activity of Nav1.2 and Nav1.5 channels but not of Nav1.4, Nav1.6 and Nav1.7 channels. Lu AE98134 can be used to analyze pathophysiological functions of the Nav1.1 channel in various central nervous system diseases, including cognitive restoring in schizophrenia, et al .
|
-
- HY-Y1058
-
BHA
|
Fungal
|
Infection
|
Benzohydroxamic acid (BHA) is a chitin deacetylase (CDA) inhibitor with significant antifungal activity. The Ki values of BHA against the CDAs of Verticillium dahliae and Puccinia striiformis f. sp. tritici are 8.31 μM and 9.83 μM, respectively. Benzohydroxamic acid can restore the defense responses of infected host plants, upregulate the expression of defense-related genes, and reduce the growth and reproduction of fungi in plants. Benzohydroxamic acid can be used in the research of the field of controlling agricultural fungal diseases, such as various plant fungal diseases caused by Verticillium dahliae, Puccinia striiformis and other fungi, like cotton wilt and wheat stripe rust .
|
-
- HY-120793
-
TRB-N0224
|
Ras
Apoptosis
MMP
|
Inflammation/Immunology
Cancer
|
CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC50s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis .
|
-
- HY-109136
-
BAY 1101042
|
Guanylate Cyclase
|
Cardiovascular Disease
Metabolic Disease
|
Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic kidney disease (CKD) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF) .
|
-
- HY-137441
-
PU-HZ151
|
HSP
|
Neurological Disease
Cancer
|
Icapamespib (PU-HZ151; PU-AD) is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .
|
-
- HY-141659
-
CMPD-39
2 Publications Verification
|
Mitophagy
Deubiquitinase
|
Neurological Disease
|
CMPD-39 is a selective non-covalent inhibitor of the ubiquitin-specific protease USP30 (IC50=~20 nM), with high selectivity over other DUB family members (1-100 μM). CMPD-39 inhibits the deubiquitinating activity of USP30, enhances the ubiquitination of mitochondrial proteins TOMM20 and SYNJ2BP; thus, CMPD-39 promotes phosphoubuitin accumulation, thereby accelerating mitochondrial autophagy (mitophagy) and peroxisomal autophagy (pexophagy). CMPD-39 significantly restores impaired mitochondrial function in dopaminergic neurons derived from Parkinson's disease patients .
|
-
- HY-137441A
-
PU-HZ151 hydrochloride
|
HSP
|
Neurological Disease
Cancer
|
Icapamespib (PU-HZ151; PU-AD) hydrochloride is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib hydrochloride can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib hydrochloride can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib hydrochloride can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .
|
-
- HY-P99048
-
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-P10424
-
|
PD-1/PD-L1
|
Cancer
|
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research .
|
-
- HY-149250
-
|
MDM-2/p53
Apoptosis
|
Cancer
|
MDMX/MDM2-IN-2 is a potent p53-MDM2/MDMX dual inhibitors with Kis of 0.23 μM and 2.45 μM for MDM2 and MDMX, respectively. MDMX/MDM2-IN-2 inhibits the binding of p53 and MDM2 proteins. MDMX/MDM2-IN-2 restores the function of p53 and enables cell cycle arrest and apoptosis. MDMX/MDM2-IN-2 inhibits cell migration and invasion. MDMX/MDM2-IN-2 has antitumor activity .
|
-
- HY-162643
-
|
PD-1/PD-L1
PARP
|
Cancer
|
Antitumor agent-169 (Compound B3) is a dual inhibitor PD-1/PD-L1 interaction and PARP7, with IC50s of 0.426 μM and 2.50 nM. Antitumor agent-169 exhibits an affinity to human PD-L1, with Ki of 20.2 nM. Antitumor agent-169 restores the T cell function, increases IFN-γ secretion. Antitumor agent-169 inhibits cell viability of MDA-MB-231 and Jurkat T, exhibits antitumor efficacy against melanoma in mouse model and good pharmacokinetic characteristics .
|
-
- HY-126823
-
PGSK diacetate (5/6-mixture)
|
Fluorescent Dye
|
Others
|
Phen green SK (PGSK) diacetate (PGSK diacetate (5/6-mixture)) is a metal ion-sensitive fluorescent probe that can penetrate cell membranes. Phen green SK (PGSK) diacetate can react with a variety of metal ions, including Fe 2+, Cd 2+, Co 2+, Ni 2+, Zn 2+, etc. Phen green SK (PGSK) diacetate chelates Fe 2+, resulting in fluorescence quenching, which can be restored when a membrane-permeable chelator is added, thereby reflecting the changes in the intracellular chelatable iron pool. The excitation/emission maxima of Phen green SK diacetate are 507/532 nm, respectively .
|
-
- HY-159921
-
|
Microtubule/Tubulin
|
Cancer
|
Tubulin Polymerization-IN-1 prodrug (Compound 2b) is a palladium (Pd)-mediated tubulin polymerization inhibitor prodrug. Developed based on colchicine binding site inhibitors (CBSIs), it reduces toxicity and enhances targeted release properties. Compared to the parent compound, Tubulin Polymerization-IN-1 prodrug exhibited 68.3-fold lower cytotoxicity, which can be restored in situ in the presence of Pd resin. Mechanistic studies showed that its anticancer activity is consistent with CBSIs. In vivo, Tubulin Polymerization-IN-1 prodrug significantly inhibited tumor growth (63.2%) when activated by Pd resin. It holds promise for research in the field of anticancer therapy .
|
-
- HY-19310
-
|
Adenosine Receptor
|
Cardiovascular Disease
Metabolic Disease
|
AMP-579 is an adenosine receptor agonist that primarily targets adenosine A1 and A2A receptors (with Ki values of 1.7 and 4.5 nM for the A1 receptor in rat brain and adipocytes, and a Ki value of 56 nM for the A2A receptor in rat brain). AMP-579 inhibits lipolysis, restores insulin-dependent glucose transport, and reduces heart rate through the activation of A1 receptors, while it induces vasodilation, particularly in coronary arteries, through the activation of A2A receptors (with an IC50 of 0.3 μM in porcine coronary arterial rings). AMP 579 shows potential for application in cardioprotection and the treatment of acute myocardial infarction .
|
-
- HY-161410
-
|
PROTACs
Apoptosis
Bcl-2 Family
|
Cancer
|
WH244 is a second generation BCL-2 and BCL-xL dual depressant (PROTAC). The primary activity of WH244 is the specific degradation of BCL-2 and BCL-xL proteins (BCL-xL: DC50=0.6 nM, BCL-2: DC50=7.4 nM). WH244 promotes their ubiquitination and subsequent proteasome degradation by targeting these proteins, thereby restoring the cell's apoptosis pathway. WH244 has good antitumor activity. (Pink: BCL-2/BCL-xL ligand (HY-161415); Blue: E3 ligase ligand (HY-112078); Black: linker) .
|
-
- HY-116716
-
|
MicroRNA
|
Cancer
|
PIN1 inhibitor API-1 is a specific Pin1 (peptidyl-prolyl cis-trans isomerase NIMA-interacting 1) inhibitor (API-1) with an IC50 of 72.3 nM. PIN1 inhibitor API-1 directly and specifically binds to the Pin1 peptidyl-prolyl isomerase (PPIase) domain and potently inhibits Pin1 cis-trans isomerizing activity. PIN1 inhibitor API-1 retains the active conformation of pXPO5 and restores the ability of pXPO5 to transport pre-miRNAs from nucleus to cytoplasm, thus up-regulating the anticancer miRNA biogenesis to suppress both in vitro and in vivo hepatocellular carcinoma development .
|
-
- HY-111126
-
K67
1 Publications Verification
|
p62
Keap1-Nrf2
|
Cancer
|
K67 is a selective the interaction between Keap1 and S349 phosphorylated p62 inhibitor, with an IC50 of 1.5 μM. K67 has a weaker inhibitory effect on the interaction between Keap1 and Nrf2 (IC50 is 6.2 μM). K67 competitively binds to the binding site of Keap1 with p-p62, blocking the abnormal activation of the p62-dependent Nrf2 pathway. K67 inhibits tumor cell proliferation and enhances the sensitivity of hepatocellular carcinoma (HCC) to chemotherapeutic drugs by restoring Keap1-mediated ubiquitination and degradation of Nrf2 .
|
-
- HY-154919
-
|
YTHDF
FOXO
MMP
Pyroptosis
Interleukin Related
|
Endocrinology
Cancer
|
DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer .
|
-
- HY-149508
-
|
Keap1-Nrf2
Reactive Oxygen Species
|
Cancer
|
Nrf2-IN-3 (Compound R16) is a small-molecule NRF2 inhibitor and increases reactive oxygen species (ROS) production. Nrf2-IN-3 selectively binds KEAP1 mutants and restores their NRF2-inhibitory function by repairing the disrupted KEAP1/NRF2 interactions, leading to proteasome-dependent NRF2 degradation in cells. Nrf2-IN-3 sensitizes KEAP1-mutated tumor cells to Cisplatin (HY-17394), Gefitinib (HY-50895), and KEAP1 G333C-mutated xenograft to Cisplatin .
|
-
- HY-P99573
-
MGD-013
|
LAG-3
|
Inflammation/Immunology
Cancer
|
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .
|
-
- HY-151411
-
|
RUNX
|
Cancer
|
RUNX1/ETO tetramerization-IN-1 is a small-molecule inhibitor of RUNX1/ETO tetramerization, exhibits anti-leukemic effect. RUNX1/ETO tetramerization-IN-1 specifically targets to NHR2 of RUNX1/ETO (EC50=0.25 μM), restores gene expression down-regulated by RUNX1/ETO. RUNX1/ETO tetramerization-IN-1 inhibits the proliferation of RUNX1/ETO-depending SKNO-1 cells, and reduces the RUNX1/ETO-related tumor growth in a mouse model .
|
-
- HY-B0561
-
SC9420
|
Mineralocorticoid Receptor
Androgen Receptor
Autophagy
Calcium Channel
|
Cardiovascular Disease
Metabolic Disease
Endocrinology
Cancer
|
Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC50=24 nM) and androgen receptor (IC50=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca 2+ channels to exert antihypertensive effects .
|
-
- HY-P99048A
-
IBI308 (Anti-PD-1)
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-D1450
-
S01448
|
Fluorescent Dye
|
Cancer
|
IR-1048 is a nitroreductase (NTR)-responsive near-infrared fluorescence (NIR)/photoacoustic (PA) imaging probe and photothermal agent. IR-1048 is coupled with a nitroimidazole group to form IR-1048-MZ. IR-1048-MZ is catalytically reduced by NTR in a hypoxic environment, restoring strong near-infrared absorption and fluorescence emission (NIR II window), while activating the photothermal effect. IR-1048 relies on NTR-mediated electron transfer to relieve intramolecular fluorescence quenching, achieving specific imaging and photothermal ablation of tumor hypoxic areas. IR-1048 is mainly used for high-contrast NIR II/photoacoustic imaging and photothermal therapy research and tumor diagnosis of the tumor hypoxic microenvironment .
|
-
- HY-130625
-
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC50 of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model .
|
-
- HY-170522
-
|
HIF/HIF Prolyl-Hydroxylase
|
Inflammation/Immunology
|
ISM012-042 is an orally active PHD1 and PHD2 inhibitor with IC50 values of 1.9 and 2.5 nM, respectively. ISM012-042 (2.5 μM) can protect Caco-2 cells from DSS-induced barrier disruption. In lipopolysaccharide (LPS)-induced mouse bone marrow-derived dendritic cells (BMDC), ISM012-042 has anti-inflammatory effects and can dose-dependently reduce the expression of IL-12 subunit IL-12p35 and TNF. ISM012-042 restores intestinal barrier function and alleviates intestinal inflammation in various experimental colitis models. ISM012-042 can be used for intestinal mucosal repair and research into immune diseases .
|
-
- HY-122578
-
|
MDM-2/p53
|
Cancer
|
P53R3 is a potent p53 reactivator and restores sequence-specific DNA binding of p53 hot spot mutants, including p53 R175H, p53 R248W and p53 R273H. P53R3 induces p53-dependent antiproliferative effects with much higher specificity than PRIMA-1. P53R3 enhances the recruitment of wild-type p53 and p53 M237I to several target gene promoters. P53R3 strongly enhances the mRNA, total protein and cell surface expression of the death receptor death receptor 5 (DR5). P53R3 is used for cancer research .
|
-
- HY-131183
-
|
PROTACs
PD-1/PD-L1
|
Inflammation/Immunology
|
PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .
|
-
- HY-150229
-
|
Liposome
|
Cancer
|
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .
|
-
- HY-116497
-
|
FAK
|
Cancer
|
PH11 is a novel focal adhesion kinase (FAK) inhibitor that rapidly induces apoptosis in TRAIL-resistant PANC-1 cells when combined with TRAIL, but has no effect on normal human fibroblasts. The study found that PH11 downregulates c-FLIP through inhibition of FAK and phosphatidylinositol-3-kinase (PI3K)/AKT pathways, thereby restoring the TRAIL apoptotic pathway, suggesting that this combination therapy may provide an attractive therapeutic strategy for the safe and effective treatment of pancreatic cancer. PH11 selectively inhibits c-FLIP expression by modulating upstream signaling pathways and may represent an innovative therapeutic strategy. Although further work is needed to fully elucidate the mechanism of PH11-induced TRAIL sensitization, we believe that our results will provide a new approach to target c-FLIP without the risk of interfering with caspase-8 processing, which could potentially lead to TRAIL resistance. This study also suggests a role for the FAK/AKT signaling pathway in regulating c-FLIP expression in TRAIL-induced apoptosis, and this understanding will provide important clues to control the resistance mechanism to optimize the potential of TRAIL-based pancreatic cancer treatment.
|
-
-
-
HY-L004
-
|
2,624 compounds
|
DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair.
MCE owns a unique collection of 2,624 cell cycle/DNA damage-related compounds which can be used in the research of the same.
|
-
-
HY-L054
-
|
291 compounds
|
Endoplasmic reticulum (ER) contributes to the production and folding of approximately one third of cellular proteins, and is thus inextricably linked to the maintenance of cellular homeostasis and the fine balance between health and disease. However, some adverse factors negatively impact ER functions and protein synthesis, resulting in the activation of Endoplasmic reticulum stress (ER stress, ERS) and unfolded protein response (UPR) signaling pathways. The UPR is triggered when ER protein folding capacity is overwhelmed by cellular demand and the UPR initially aims to restore ER homeostasis and normal cellular functions. However, if this fails, then the UPR triggers cell death. Chronic ER stress and defects in UPR signaling are emerging as key contributors to a growing list of human diseases, including diabetes, neurodegeneration and cancer.
MCE Endoplasmic Reticulum Stress Compound Library contains 291 ER stress-related compounds that mainly target PERK, IRE1, ATF6, etc. MCE ER stress library is a useful tool for researching ER stress and related diseases.
|
Cat. No. |
Product Name |
Type |
-
- HY-19980G
-
APR-246 (GMP); PRIMA-1Met (GMP)
|
Fluorescent Dye
|
Eprenetapopt (GMP) (APR-246(GMP)) is Eprenetapopt (HY-19980) in GMP grade. Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance .
|
Cat. No. |
Product Name |
Type |
-
- HY-150229
-
|
Drug Delivery
|
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .
|
-
- HY-W104821
-
|
Indicators
|
Rosolic Acid is an activator of Nrf2, as well as its downstream targets. Rosolic Acid increases the levels of angiogenic factors, decreases inflammation (TNF-α and IL-1β) and apoptotic markers (CXCL10 and CCL2). Rosolic Acid restores the function of pancreatic cells and protects endothelial cells (ECs) from endoplasmic reticulum stressed .
|
-
- HY-19980G
-
APR-246 (GMP); PRIMA-1Met (GMP)
|
Biochemical Assay Reagents
|
Eprenetapopt (GMP) (APR-246(GMP)) is Eprenetapopt (HY-19980) in GMP grade. Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1930A
-
|
Integrin
|
Inflammation/Immunology
|
Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .
|
-
- HY-P3333
-
|
MHC
|
Inflammation/Immunology
Cancer
|
KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .
|
-
- HY-P3333A
-
|
MHC
|
Inflammation/Immunology
Cancer
|
KSPWFTTL TFA is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL TFA can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .
|
-
- HY-P2624A
-
|
PAK
|
Metabolic Disease
|
st-Ht31 ammonium is a membrane-permeable peptide inhibitor of?protein kinase A (PKA) anchoring. st-Ht31 ammonium induces robust cholesterol/phospholipid efflux. st-Ht31 ammonium completely reverses foam cell formation and restores the metabolic health of macrophage .
|
-
- HY-P1930
-
|
Integrin
|
Inflammation/Immunology
|
Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .
|
-
- HY-P10015
-
|
Peptides
|
Endocrinology
|
Orenetide is an innovative peptide drug developed in the study to restore sexual desire and concomitant functions in women with HSDD (Hypoactive desire disorder)
|
-
- HY-121520
-
-
- HY-P5183
-
|
Sodium Channel
|
Neurological Disease
|
Hm1a is a disulfide-rich spider-venom peptide, and a NaV1.1 activator. Hm1a restores the function of inhibitory interneurons in Dravet syndrome (DS) mouse model .
|
-
- HY-169675
-
-
- HY-P2624
-
|
PAK
|
Metabolic Disease
|
st-Ht31 is a membrane-permeable peptide inhibitor of protein kinase A (PKA) anchoring. st-Ht31 induces robust cholesterol/phospholipid efflux. st-Ht31 completely reverses foam cell formation and restores the metabolic health of macrophage .
|
-
- HY-P3355
-
|
iGluR
|
Neurological Disease
|
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
|
-
- HY-P10950
-
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers .
|
-
- HY-P10439
-
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a KD of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research .
|
-
- HY-P3354
-
|
iGluR
|
Neurological Disease
|
p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
|
-
- HY-P3736
-
MP-2
|
Interleukin Related
|
Cancer
|
Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research .
|
-
- HY-P10404
-
|
α-synuclein
|
Others
Neurological Disease
|
PDpep1.3 is a peptide inhibitor of α-synuclein that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions .
|
-
- HY-P10424
-
|
PD-1/PD-L1
|
Cancer
|
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9940
-
|
Factor VIII
|
Cardiovascular Disease
|
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .
|
-
- HY-P9993
-
LY-3462817
|
PD-1/PD-L1
|
Inflammation/Immunology
|
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. Peresolimab can be used in research of rheumatoid arthritis .
|
-
- HY-P99590
-
ACE-011
|
TGF-β Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
|
-
- HY-P99431
-
Alomfilimab; SAR 445256
|
CD28
|
Inflammation/Immunology
Cancer
|
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 + TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
|
-
- HY-P99048
-
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-108739
-
BI 655075
|
Thrombin
|
Cardiovascular Disease
|
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
|
-
- HY-P991257
-
|
Interleukin Related
|
Cancer
|
MK-1966 is a humanized monoclonal antibody inhibitor targeting interleukin-10 (IL-10). MK-1966 blocks the inhibitory effects of IL-10 on immune cells such as macrophages and dendritic cells to restore anti-tumor immune responses. MK-1966 is promising for research of cancers .
|
-
- HY-P991443
-
|
CD73
|
Cancer
|
IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991440
-
|
TNF Receptor
|
Inflammation/Immunology
|
AMG-966 is a human bispecific antibody (bsAb) targeting TNFSF15/TL1A & TNFα. AMG 966 restores the ability of the aglycosylated Fc domain to bind to FcγRIa and FcγRIIa, leading to the formation of antidrug antibodies (ADA). AMG-966 can be used in Crohn's disease and Ulcerative colitis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991441
-
|
TREM receptor
Apoptosis
|
Neurological Disease
|
VGL101 is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. VGL101 is a pSYK agonist (EC50: 0.77 nM). VGL101 restores the survival ability of microglia and monocyte-derived macrophages under ALSP pathological conditions, inhibits apoptosis, and promotes the restoration of cell morphology to a state similar to that of normal activated CSF1R. VGL101 can be used in Leukoencephalopathies research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P99573
-
MGD-013
|
LAG-3
|
Inflammation/Immunology
Cancer
|
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .
|
-
- HY-P99048A
-
IBI308 (Anti-PD-1)
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B1804S2
-
|
Tricaprilin-d15 (Trioctanoin-d15) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
-
- HY-B1804S1
-
|
Tricaprilin-d50 (Trioctanoin-d50) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
-
- HY-B1804S
-
|
Tricaprilin- 13C3 (Trioctanoin- 13C3) is a 13C-labeled Tricaprilin (HY-B1804) . Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-P10950
-
|
|
Alkynes
|
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers .
|
-
- HY-159921
-
|
|
Alkynes
|
Tubulin Polymerization-IN-1 prodrug (Compound 2b) is a palladium (Pd)-mediated tubulin polymerization inhibitor prodrug. Developed based on colchicine binding site inhibitors (CBSIs), it reduces toxicity and enhances targeted release properties. Compared to the parent compound, Tubulin Polymerization-IN-1 prodrug exhibited 68.3-fold lower cytotoxicity, which can be restored in situ in the presence of Pd resin. Mechanistic studies showed that its anticancer activity is consistent with CBSIs. In vivo, Tubulin Polymerization-IN-1 prodrug significantly inhibited tumor growth (63.2%) when activated by Pd resin. It holds promise for research in the field of anticancer therapy .
|
Cat. No. |
Product Name |
|
Classification |
-
- HY-145721A
-
GED-0301 sodium
|
|
Antisense Oligonucleotides
|
Mongersen sodium is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen sodium restores TGF-β1 activity leading to inhibition of inflammatory signals. Mongersen sodium can attenuate Crohn's disease-like experimental colitis in mice .
|
-
- HY-132584A
-
SRP-4045 sodium
|
|
Antisense Oligonucleotides
|
Casimersen sodium is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass. Casimersen sodium binds to exon 45 of dystrophin pre-mRNA, restores the open-reading frame (by skipping exon 45) resulting in the production of an internally truncated but functional dystrophin protein. Casimersen sodium can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
- HY-132586A
-
NS-065/NCNP-01 sodium
|
|
Antisense Oligonucleotides
|
Viltolarsen (NS-065/NCNP-01) sodium is a phosphorodiamidate morpholino antisense oligonucleotide. Viltolarsen sodium binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. Viltolarsen sodium has the potential for Duchenne muscular dystrophy (DMD) research .
|
-
- HY-153480A
-
BAX499 sodium
|
|
Aptamers
|
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
|
-
- HY-150229
-
|
|
Cationic Lipids
|
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .
|
-
- HY-145721
-
GED-0301
|
|
Antisense Oligonucleotides
|
Mongersen (GED-0301) is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen restores TGF-β1 activity leading to inhibition of inflammatory signals. Mongersen can attenuate Crohn's disease-like experimental colitis in mice .
|
-
- HY-132584
-
SRP-4045
|
|
Antisense Oligonucleotides
|
Casimersen (SRP-4045) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass. Casimersen binds to exon 45 of dystrophin pre-mRNA, restores the open-reading frame (by skipping exon 45) resulting in the production of an internally truncated but functional dystrophin protein. Casimersen can be used for the research of Duchenne muscular dystrophy (DMD) .
|
-
- HY-132586
-
NS-065/NCNP-01
|
|
Antisense Oligonucleotides
|
Viltolarsen (NS-065/NCNP-01) is a phosphorodiamidate morpholino antisense oligonucleotide. Viltolarsen binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. Viltolarsen has the potential for Duchenne muscular dystrophy (DMD) research .
|
-
- HY-153480
-
BAX499
|
|
Aptamers
|
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
|
-
- HY-160062
-
|
|
Aptamers
|
S2.2 aptamer sodium is a nucleic acid aptamer targeting the mucin MUC1 and can be used for targeted imaging of MCF-7 cancer cells. S2.2 aptamer sodium was labeled with Cy5, and when fluorescent silicon nanodots (SiND) were present, the fluorescence was quenched; when MUC1 was also present, the fluorescence was restored. S2.2 aptamer sodium detects MUC1 with a linear range of 3.33-250 nM .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: